| P50 | author | David J. Waxman | Q30506493 |
| | Joshua C. Doloff | Q55536546 |
| P2093 | author name string | Joshua C Doloff | |
| P2860 | cites work | Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells | Q24308708 |
| | AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | Q28251373 |
| | Cancer and the chemokine network | Q28269751 |
| | Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer | Q28376841 |
| | Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice | Q28594763 |
| | Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 |
| | Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib | Q33400232 |
| | Platelet lifespan | Q33467358 |
| | Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme | Q33518926 |
| | The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses | Q33916569 |
| | Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients | Q57220173 |
| | Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo | Q72080775 |
| | Induction of Fas and Fas-ligand expression in plasmacytoma cells by a cytotoxic factor secreted by murine macrophages | Q73378602 |
| | Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain | Q82925098 |
| | Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis | Q33930139 |
| | Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice | Q34432972 |
| | Oncogenic stress sensed by the immune system: role of natural killer cell receptors | Q34473267 |
| | The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. | Q34550543 |
| | Cell death mechanisms induced by cytotoxic lymphocytes | Q34605017 |
| | Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. | Q36274479 |
| | Natural killer cells in breast cancer cell growth and metastasis in SCID mice | Q36409402 |
| | Pharmacokinetic considerations in the treatment of CNS tumours | Q36574934 |
| | The anticancer immune response: indispensable for therapeutic success? | Q36677608 |
| | Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy | Q36689936 |
| | Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones | Q36861548 |
| | Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors | Q36883658 |
| | Dendritic cell-endothelial cell cross-talk in angiogenesis | Q36907764 |
| | Immunological aspects of cancer chemotherapy | Q37039588 |
| | Humanized SCID mouse models for biomedical research | Q37164243 |
| | Killer dendritic cells: IKDC and the others | Q37191524 |
| | Combination of antiangiogenesis with chemotherapy for more effective cancer treatment | Q37346912 |
| | Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited | Q37403323 |
| | Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models | Q37435219 |
| | Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression | Q37581751 |
| | Metronomic chemotherapy: new rationale for new directions | Q37763502 |
| | Effect of NKG2D ligand expression on host immune responses | Q37764003 |
| | Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model | Q38282828 |
| | Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib | Q38568650 |
| | Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation | Q39808301 |
| | Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment | Q39856522 |
| | Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. | Q39916513 |
| | Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies | Q40222725 |
| | Thrombospondin-1 promotes proliferative healing through stabilization of PDGF. | Q40697052 |
| | Chemotherapy induces tumor clearance independent of apoptosis | Q41164012 |
| | Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation | Q41267230 |
| | In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice | Q42268397 |
| | Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. | Q45950526 |
| | Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia | Q46114146 |
| | Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model | Q46120052 |
| | Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology | Q46175398 |
| | Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. | Q46956205 |
| | Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. | Q53473696 |
| | Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. | Q53970403 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1103-1115 | |
| P577 | publication date | 2012-01-11 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression | |
| P478 | volume | 72 | |